1 349

Cited 13 times in

Ocular hypotensive effects of topically administered agmatine in a chronic ocular hypertensive rat model

Authors
 Samin Hong  ;  Chan Yun Kim  ;  Won Seok Lee  ;  Jongwoo Shim  ;  Ho Yeop Yeom  ;  Gong Je Seong 
Citation
 EXPERIMENTAL EYE RESEARCH, Vol.90(1) : 97-103, 2010 
Journal Title
EXPERIMENTAL EYE RESEARCH
ISSN
 0014-4835 
Issue Date
2010
MeSH
Administration, Topical ; Agmatine/administration & dosage* ; Animals ; Antihypertensive Agents/administration & dosage* ; Cell Count ; ChronicDisease ; Disease Models, Animal* ; Intraocular Pressure/drugeffects* ; Male ; Neuroprotective Agents/administration & dosage ; OcularHypertension/drug therapy* ; Ophthalmic Solutions/administration & dosage ; Rats ; Rats, Sprague-Dawley ; Retinal Ganglion Cells/drugeffects ; Retinal Ganglion Cells/pathology
Keywords
agmatine ; glaucoma ; intraocular pressure ; neuroprotection ; retinal ganglion cell
Abstract
Agmatine, a primary polyamine and potential neuromodulator, exhibits a high affinity to the alpha2-adrenergic receptor as well as imidazoline receptors. As alpha2-adrenergic receptor agonists display positive ocular hypotensive effects, we assessed whether agmatine effectively lowers intraocular pressure (IOP) using a chronic ocular hypertensive rat model. We raised IOP in unilateral eyes of Sprague-Dawley rats by cauterizing three episcleral veins per eye. Four weeks later, we topically administered 10(-3) M agmatine solution 4 times a day for 6 consecutive weeks. After confirming the recovery of IOP to pretreatment level at 13 weeks after cauterization, the retinal ganglion cells (RGCs) were retrogradely labeled and counted. Eyes subjected to episcleral vein cauterization (EVC) demonstrated significant increases in IOP (48.39% increase over baseline IOP), and the elevated IOP was well maintained until 12 weeks. Topically administered agmatine powerfully lowered IOP to 30.29% of its pretreatment level, and the associated washout period was about two weeks. EVC was associated with a 55.44% loss of RGCs in the control group, but agmatine appeared to attenuate this RGC loss to 18.65%. Overall, topically administered agmatine appeared to effectively lower IOP and rescue RGCs in a chronic ocular hypertensive rat model. Although the mechanism underlying these effects is not yet established, it is possible that agmatine offers a powerful new ocular hypotensive agent for eyes with chronic ocular hypertension and/or glaucoma.
Full Text
http://www.sciencedirect.com/science/article/pii/S001448350900284X
DOI
10.1016/j.exer.2009.09.016
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Chan Yun(김찬윤) ORCID logo https://orcid.org/0000-0002-8373-9999
Seong, Gong Je(성공제) ORCID logo https://orcid.org/0000-0002-5456-4296
Yeom, Ho Yeop(염호엽)
Hong, Sa Min(홍사민)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/100436
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links